Nasdaq: VTAE

Vitae Pharmaceuticals

Vitae Pharmaceuticals is a clinical stage biotechnology company pursuing “difficult-to drug” target. They are developing a robust and growing portfolio of novel product candidates generated by Contour®, their proprietary computationally-based SBDD platform. Their team of accomplished scientists utilizes Contour® to rapidly discover highly potent and selective product candidates for validated targets against which the industry has traditionally struggled to develop drugs. They address multiple disease areas including diabetes, Alzheimer’s disease, autoimmune disorders, atopic dermatitis, and acute coronary syndrome.